Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

Completed

Conditions: Carcinoma, Renal Cell

First Posted Date: 2019-04-16

Last Posted Date: 2021-12-13

Lead Sponsor: Pfizer

Target Recruit Count: 62

Registration Number: NCT03916458

Locations: 🇪🇸
Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
Hospital Universitario Son Espases, Palma de Mallorca, Mallorca, Spain
🇪🇸
Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Tenerife, Spain

and more 28 locations

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: PF-04965842 200 mg
Drug: PF-04965842 100 mg
Drug: Placebo

First Posted Date: 2019-04-16

Last Posted Date: 2023-02-08

Lead Sponsor: Pfizer

Target Recruit Count: 46

Registration Number: NCT03915496

Locations: 🇺🇸
The Indiana Clinical Trials Center, PC - Dermatology Research, Plainfield, Indiana, United States
🇺🇸
Keck School of Medicine of USC - IDS Pharmacy, Los Angeles, California, United States
🇺🇸
ForCare Clinical Research, Tampa, Florida, United States

and more 8 locations

An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis

Phase 2

Terminated

Conditions: Brain Metastases

Interventions: Drug: encorafenib
Drug: binimetinib

First Posted Date: 2019-04-11

Last Posted Date: 2023-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT03911869

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Rocky Mountain Lions Eye Institute (RMLEI), Aurora, Colorado, United States
🇦🇺
Crows Nest Eye Surgery, Crows Nest, New South Wales, Australia

and more 22 locations

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Lorlatinib

First Posted Date: 2019-04-10

Last Posted Date: 2024-11-22

Lead Sponsor: Pfizer

Target Recruit Count: 109

Registration Number: NCT03909971

Locations: 🇨🇳
The first hospital of jilin university, Changchun, Jilin, China
🇨🇳
Tangdu Hospital of Fourth Military Medical University, Xi'an, Shanxi, China
🇨🇳
Sichuan Province Cancer Hospital/Department of Pulmonary Tumor, Chengdu, Sichuan, China

and more 18 locations

LORA-PITA IV General Investigation

Completed

Conditions: Status Epilepticus

Interventions: Drug: Lorazepam

First Posted Date: 2019-04-05

Last Posted Date: 2025-03-10

Lead Sponsor: Pfizer

Target Recruit Count: 206

Registration Number: NCT03905798

Locations: 🇯🇵
Pfizer Local Country office, Tokyo, Shibuya-ku, Japan

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: PF-06700841
Drug: Vehicle (Placebo)

First Posted Date: 2019-04-04

Last Posted Date: 2021-03-29

Lead Sponsor: Pfizer

Target Recruit Count: 292

Registration Number: NCT03903822

Locations: 🇺🇸
Center for Dermatology and Plastic Surgery, Scottsdale, Arizona, United States
🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸
California Dermatology & Clinical Research Institute, Encinitas, California, United States

and more 70 locations

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: PF-06826647 or Placebo
Drug: PF-06826647

First Posted Date: 2019-03-29

Last Posted Date: 2021-08-27

Lead Sponsor: Pfizer

Target Recruit Count: 179

Registration Number: NCT03895372

Locations: 🇺🇸
DelRicht Research, Baton Rouge, Louisiana, United States
🇨🇦
Centre Radiologique de l'Estrie, Sherbrooke, Quebec, Canada
🇨🇦
Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada

and more 40 locations

Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

Completed

Conditions: Ulcerative Colitis
Crohn's Disease

Interventions: Drug: Infliximab [infliximab biosimilar 3]

First Posted Date: 2019-03-21

Last Posted Date: 2025-03-21

Lead Sponsor: Pfizer

Target Recruit Count: 428

Registration Number: NCT03884439

Locations: 🇯🇵
Pfizer Local Country Office, Tokyo, Japan

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Infliximab [infliximab biosimilar 3]

First Posted Date: 2019-03-21

Last Posted Date: 2025-04-13

Lead Sponsor: Pfizer

Target Recruit Count: 77

Registration Number: NCT03885037

Locations: 🇯🇵
Pfizer Local Country Office, Tokyo, Japan

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Completed

Conditions: Psoriasis Arthropathica
Pustular Psoriasis
Erythrodermic Psoriasis
Psoriasis Vulgaris

Interventions: Drug: Infliximab [infliximab biosimilar 3]

First Posted Date: 2019-03-21

Last Posted Date: 2025-06-19

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT03885089

Locations: 🇯🇵
Pfizer Local Country Office, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy